Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #2 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited (this stock) | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 3,080 | 1,180 | 902 | ₹ |
| March 31, 2026 | 2,831 | 963 | 751 | ₹ |
| Dec. 31, 2025 | 2,604 | 780 | 583 | ₹ |
| Sept. 30, 2025 | 2,715 | 912 | 689 | ₹ |
| June 30, 2025 | 2,410 | 733 | 545 | ₹ |
| March 31, 2025 | 2,585 | 864 | 662 | ₹ |
| Dec. 31, 2024 | 2,319 | 726 | 589 | ₹ |
| Sept. 30, 2024 | 2,338 | 722 | 510 | ₹ |
| June 30, 2024 | 2,118 | 604 | 430 | ₹ |
| March 31, 2024 | 2,303 | 713 | 538 | ₹ |
| Dec. 31, 2023 | 1,855 | 489 | 358 | ₹ |
| Sept. 30, 2023 | 1,909 | 469 | 348 | ₹ |
| June 30, 2023 | 1,778 | 492 | 356 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 10,560 | 3,388 | 2,568 |
| March 31, 2025 | 9,360 | 2,916 | 2,191 |
| March 31, 2024 | 7,845 | 2,163 | 1,600 |
| March 31, 2023 | 7,768 | 2,369 | 1,823 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 2,738 | -2,219 | -804 | 2,520 | 218 |
| March 31, 2025 | 1,653 | -804 | -799 | 1,438 | 215 |
| March 31, 2024 | 1,261 | -269 | -799 | 1,003 | 258 |
| March 31, 2023 | 2,460 | -2,708 | -797 | 473 | 1,987 |
| March 31, 2022 | 1,912 | -2,195 | -532 | 713 | 1,199 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 20,033 | 16,761 | 16,708 | 0 | 0 | 11,096 | 2,043 | 128 | 6,515 | 3,954 |
| March 31, 2025 | 16,932 | 14,969 | 14,916 | 2 | 0 | 10,081 | 1,452 | 415 | 5,437 | 3,236 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
